News Review: Agrium Inc. (USA) (NYSE:AGU), VIVUS, Inc. (NASDAQ:VVUS)

Lakeway, TX -- (SBWIRE) -- 03/05/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Agrium Inc. (USA) (NYSE:AGU) today announced of commencing mail of its Proxy Circular in advance of the Annual General Meeting of Shareholders that will take place in Calgary, Alberta on April 9, 2013 which includes a letter to Agrium shareholders from Board Chair Victor Zaleschuk, as well as detailed reasons why Agrium shareholders should vote FOR Agrium's Board slate, using only the WHITE proxy.

How Should Investors Trade AGU After The Recent Movement? Find Out Here

"This is a simple choice between Agrium's highly successful strategy that has delivered two consecutive years of record financial results and generated a 467% shareholder return since 2005, versus JANA Partners'ill-conceived scheme to break up the company and take other actions that will destroy shareholder value," said Victor Zaleschuk, Board Chair. "Agrium shareholders need to act today to protect the value of their investment by voting for Agrium's Board nominees.

The election for the Board of Directors has become a choice between two competing visions for Agrium's future one being endorsed by Agrium's Board and management, and has the support of an overwhelming majority of Agrium's large institutional shareholders and the equity research community.

The other vision is being promoted by a New York-based activist hedge fund called JANA Partners. JANA wants Agrium to abandon its current strategy, break itself into three small pieces, and take other actions that will destroy shareholder value.

VIVUS, Inc. (NASDAQ:VVUS) shares fell by 14 cents or 1.40% to $10.20 following the news of Qsymia price might get lowered.

Is VVUS Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Andrew Berens of Bloomberg Industries said that VIVUS will start offering 30-days of medium-dose Qsymia for maximum out-of-pocket cost of $75.

With 14-day free trial program on low-dose Qsymia, patients will be able to get six weeks of therapy for $75, which is 70% below the list price.

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.